IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$39.85 USD
+0.83 (2.13%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $39.86 +0.01 (0.03%) 6:26 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for IDEAYA Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 525 | 365 | 247 | 284 | 99 |
Receivables | 0 | 0 | 1 | 2 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 5 | 3 | 3 | 3 |
Total Current Assets | 533 | 370 | 251 | 289 | 102 |
Net Property & Equipment | 6 | 7 | 5 | 4 | 5 |
Investments & Advances | 107 | 8 | 121 | 0 | 2 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 0 | 0 | 0 | 0 |
Total Assets | 649 | 388 | 381 | 298 | 113 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 4 | 2 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 19 | 17 | 12 | 9 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 9 | 29 | 28 | 0 |
Total Current Liabilities | 27 | 32 | 45 | 39 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 5 | 31 | 56 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 28 | 39 | 80 | 100 | 13 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 969 | 588 | 479 | 325 | 193 |
Retained Earnings | -348 | -235 | -177 | -127 | -92 |
Other Equity | 1 | -3 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 621 | 349 | 302 | 198 | 100 |
Total Liabilities & Shareholder's Equity | 649 | 388 | 381 | 298 | 113 |
Total Common Equity | 621 | 349 | 302 | 198 | 100 |
Shares Outstanding | 64.40 | 48.10 | 38.50 | 29.00 | 20.30 |
Book Value Per Share | 9.64 | 7.27 | 7.83 | 6.84 | 4.95 |
Fiscal Year End for IDEAYA Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 525 | 469 | 494 | 339 |
Receivables | NA | 0 | 7 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 8 | 7 | 8 | 4 |
Total Current Assets | NA | 533 | 482 | 502 | 344 |
Net Property & Equipment | NA | 6 | 6 | 7 | 7 |
Investments & Advances | NA | 107 | 42 | 16 | 12 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 0 |
Total Assets | NA | 649 | 533 | 528 | 365 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 7 | 5 | 6 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 19 | 16 | 15 | 17 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 1 | 3 | 6 |
Total Current Liabilities | NA | 27 | 25 | 25 | 30 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 28 | 25 | 26 | 31 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 969 | 823 | 790 | 594 |
Retained Earnings | NA | -348 | -314 | -287 | -259 |
Other Equity | NA | 1 | -1 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 621 | 508 | 502 | 334 |
Total Liabilities & Shareholder's Equity | NA | 649 | 533 | 528 | 365 |
Total Common Equity | 0 | 621 | 508 | 502 | 334 |
Shares Outstanding | 74.50 | 64.40 | 57.50 | 57.20 | 48.30 |
Book Value Per Share | 0.00 | 9.64 | 8.84 | 8.77 | 6.91 |